Referral Pathway for Esketamine (SPRAVATO Nasal Spray) in Treatment-Resistant Depression?

In this video we guide you through the development and documentation of a Personal Recovery Plan for a patient with treatment-resistant depression TRD, including the issues and risks identified, establishing recovery goals, proposed interventions and treatment, and referrals required for further management.

We provide specific information on referral for treatment with a novel rapid-acting antidepressant (esketamine) for patients with treatment-resistant depression TRD.

For a list of approved treatment centres where you can refer patients for esketamine treatment, please scan the QR code below: